Department of Medicine at the University of Vermont School of Medicine and Fletcher Allen Health Care, Burlington, Vermont; The Cardiovascular Research Institute, Burlington, Vermont.
Division of Cardiology, Hartford Hospital, Hartford, Connecticut.
Heart Rhythm. 2015 Jul;12(7):1548-57. doi: 10.1016/j.hrthm.2015.03.048. Epub 2015 Mar 28.
Cardiac resynchronization therapy (CRT) typically is attempted with biventricular pacing (BiVP). One-third of patients are nonresponders. His-bundle pacing (HBP) has been evaluated as an alternative means of effecting CRT because it generates truly physiologic ventricular activation, as evidenced in part by the morphologic identity between normally conducted and paced QRS complexes.
The purpose of this study was to assess the feasibility of, and clinical response to, permanent HBP as an alternative to BiVP in CRT-indicated patients.
Patients were implanted with a right atrial pacing lead, defibrillation lead, left ventricular (LV) lead via the coronary sinus, and HBP lead. His and LV leads were plugged into the LV port via a Y-adapter. After successful implant, patients were randomized in single patient-blinded fashion to either HBP or BiVP. After 6 months, patients were crossed over to the other pacing modality and followed for another 6 months. Quality-of-life assessments, echocardiographic measurements, New York Heart Association classification, and 6-minute hall walk test were obtained at baseline and at each 6-month follow-up.
Twenty-nine patients were enrolled; 21 (72%) demonstrated electrical resynchronization (QRS narrowing) at implant. Twelve patients completed the crossover analysis at 1 year. Clinical outcomes (quality of life, New York Heart Association functional class, 6-minute hall walk test, LV ejection fraction) were significantly improved for both pacing modes compared with baseline measures.
In this crossover comparison between HBP and BiVP, HBP was found to effect an equivalent CRT response. QRS narrowing was observed in 21 of 29 patients, suggesting this approach may be feasible in more patients with left bundle branch block than previously assumed.
心脏再同步治疗(CRT)通常采用双心室起搏(BiVP)。三分之一的患者对其无反应。希氏束起搏(HBP)已被评估为实现 CRT 的另一种手段,因为它可以产生真正的生理性心室激动,这部分可以通过正常传导和起搏 QRS 复合体之间的形态学相似性来证明。
本研究旨在评估在 CRT 适应证患者中,将永久性 HBP 作为 BiVP 的替代方法的可行性和临床反应。
患者植入右心房起搏导线、除颤导线、经冠状窦的左心室(LV)导线和 HBP 导线。His 和 LV 导线通过 Y 型适配器插入 LV 端口。植入成功后,患者以单患者盲法随机分为 HBP 或 BiVP 组。6 个月后,患者交叉至另一种起搏模式,并随访 6 个月。在基线和每 6 个月的随访时进行生活质量评估、超声心动图测量、纽约心脏协会分类和 6 分钟步行试验。
共纳入 29 例患者;21 例(72%)在植入时表现出电同步(QRS 变窄)。12 例患者在 1 年时完成了交叉分析。与基线测量相比,两种起搏模式的临床结局(生活质量、纽约心脏协会功能分级、6 分钟步行试验、LV 射血分数)均显著改善。
在 HBP 与 BiVP 的交叉比较中,发现 HBP 可产生等效的 CRT 反应。29 例患者中有 21 例观察到 QRS 变窄,这表明与之前的假设相比,这种方法可能更适用于更多左束支传导阻滞患者。